Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) EBT Margin Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -419.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 110.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 458.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 507.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -287.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 772.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 233.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -464.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | -918,039.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -918,039.00 |
| Dec 31, 2025 | 902,483.00 |
| Sep 30, 2025 | -574,705.00 |
| Jun 30, 2025 | 254,119.00 |
| Mar 31, 2025 | -351,449.00 |
| Dec 31, 2024 | -660,592.00 |
| Sep 30, 2024 | 273,146.00 |
| Jun 30, 2024 | -246,681.00 |
| Mar 31, 2024 | 111,822.00 |
| Dec 31, 2023 | -181,313.00 |
| Sep 30, 2023 | -947,108.00 |
| Jun 30, 2023 | -220,547.00 |
| Mar 31, 2023 | -232,737.00 |
| Dec 31, 2022 | 16,429.00 |
| Sep 30, 2022 | 320,075.00 |